Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
NCT ID: NCT00583622
Last Updated: 2013-05-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
13 participants
INTERVENTIONAL
2007-12-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
NCT00085358
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00079430
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT01097746
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01081262
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels.
Carboplatin is designed to damage the DNA (the genetic material) of cancer cells, which may cause them to die.
Melphalan is designed to damage the DNA of cells, which may cause cancer cells to die.
Docetaxel is designed to stop the growth of cancer cells, which may cause the cells to die.
Gemcitabine is designed to disrupt the growth of cancer cells, which may cause cancer cells to die. It may also help docetaxel, carboplatin, and melphalan to be more effective by stopping tumor cells from repairing damage caused by these drugs.
Topotecan is designed to damage the DNA of cells, which may cause cancer cells to die.
Cyclophosphamide is designed to damage the DNA of cells, which may cause cancer cells to die.
Stem Cell Removal:
Before you begin receiving the study drugs, you will have apheresis done to collect some of your stem cells as a part of your standard of care. Apheresis is the process of removing part of the blood (such as platelets or white blood cells) from the body in order to remove certain elements, such as stem cells. Then, the rest of the blood is returned back to your body.
Apheresis will be done through a central venous catheter (CVC), usually in the chest. A CVC is a sterile flexible tube that will be placed into a large vein while you are under local anesthesia. Your doctor will explain these procedures to you in more detail, and you will be required to sign a separate consent form for each procedure.
Your stem cells will be put back in your body after you finish receiving gemcitabine, docetaxel, melphalan, and carboplatin.
To prevent clotting, citrate (a blood thinner) will be added to the CVC during the apheresis procedure.
Study Drug Administration:
If you are found to be eligible to take part in this study, 2 weeks before your admission to the hospital (about 3 weeks before the stem cell transplant), you will receive bevacizumab through a the CVC over 45 minutes.
On Day 1 of your stay in the hospital, you will receive bevacizumab through the CVC over 45 minutes.
As part of standard mouth care, you will be asked to do mouthwashes 4 times a day (for 2 minutes each time) with caphosol (artificial saliva) followed by glutamine. Fifteen (15) minutes after each caphosol mouthwash, you will swish glutamine around in your mouth and gargle for 2 minutes, then spit it out. Do not swallow it.
On Day 2, through the CVC, you will receive gemcitabine over 3 hours and docetaxel over 2 hours. If you are allergic to carboplatin or older than 60 you will receive topotecan over 30 minutes.
On Day 3-5, through the CVC, you will receive gemcitabine over 3 hours, melphalan over 15 minutes, and carboplatin over 2 hours.
On Day 6, you will not receive any study drugs.
On Day 7, you will receive the stem cells through the CVC over about 30-60 minutes.
Starting the day after your stem cell transplant, as part of standard care, you will receive granulocyte-colony stimulating factor (G-CSF or filgrastim) as an injection under your skin daily, starting 1 day after the transplant, until your blood cell levels return to normal.
Starting 2 days after your transplant until 10 days after your transplant, you will receive methylprednisolone 2 times a day.
If you are allergic to carboplatin or older than 60:
On Day 1 of your stay in the hospital, you will receive bevacizumab through the CVC over 45 minutes.
On Day 2-4, through the CVC, you will receive cyclophosphamide over 2 hours and topotecan over 30 minutes. Each time you receive cyclophosphamide, you will also receive mesna to decrease the risk of bleeding in the bladder.
On Day 5-6, through the CVC, you will receive melphalan over 30 minutes and topotecan over 30 minutes.
On Day 7, you will not receive any study drugs.
On Day 8, you will receive the stem cells through the CVC over about 30-60 minutes.
Starting the day after your stem cell transplant, as part of standard care, you will receive G-CSF (filgrastim) as an injection under your skin daily, starting 1 day after the transplant, until your blood cell levels return to normal.
Study Visits:
At least once a week after the transplant, and then about 30, 60, and 100 days after your stem cell transplant, the following tests and procedures will be performed:
* Your medical history will be recorded.
* You will have a physical exam.
* You will be checked for possible reactions to the treatment, including graft-versus-host disease (GVHD) and graft failure. Graft failure occurs when donor cells may not be able to grow and multiply in your body. If this happens, there will be a high risk of infections and/or bleeding.
* Blood (about 3 tablespoons) will be drawn for routine tests and to check for tumor markers to check the status of the disease.
* Urine will be collected for routine tests.
* You will have a pelvic exam, if your doctor thinks it is needed.
* You will have an ECHO, if your doctor thinks it is needed.
* You will have a lung function test, if your doctor thinks it is needed.
* You will have CT scans of your chest, abdomen, and pelvis to check the status of the disease, if your doctor thinks it is needed.
* You will have a positron emission tomography - computed tomography (PET-CT) scan to check the status of the disease. A PET-CT is CT scan taken after a small amount of radioactive glucose (sugar) is injected into a vein to find cancer cells in the body.
These tests and procedures may be performed more often, if your doctor thinks it is needed.
End-of-Treatment Visit:
About 6 and 12 months after your stem cell transplant, then once a year after that (if your doctor thinks it is needed), the study visit tests and procedures listed above will be repeated.
Length of Study:
You will be off study after about 6 months. You will be taken off study early if the disease gets worse, if not enough stem cells can be collected, or if you experience any intolerable side effects.
Long-Term Follow-up:
If your doctor thinks it is necessary, you may have follow-up visits.
This is an investigational study. Bevacizumab is FDA approved and commercially available for the treatment of colorectal cancer. Gemcitabine, docetaxel, melphalan, and carboplatin are all FDA-approved and commercially available for the treatment of ovarian cancer. The use of bevacizumab with gemcitabine, docetaxel, melphalan, and carboplatin is investigational.
Up to 30 patients will take part in this study. All will be enrolled at MD Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bevacizumab + High-Dose Chemotherapy
Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m\^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m\^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m\^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant
Bevacizumab
5 mg/kg by vein daily over 90 minutes for 2 Days
Carboplatin
333 mg/m\^2 by vein over 2 hours for 3 Days
Docetaxel
300 mg/m\^2 by vein over 2 hours for 1 Day
Gemcitabine
1,800 mg/m2 by vein over 3 hours for 4 Days
Melphalan
50 mg/m\^2 by vein over 15 minutes for 3 Days
Stem Cell Transplant
* Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest
* Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
5 mg/kg by vein daily over 90 minutes for 2 Days
Carboplatin
333 mg/m\^2 by vein over 2 hours for 3 Days
Docetaxel
300 mg/m\^2 by vein over 2 hours for 1 Day
Gemcitabine
1,800 mg/m2 by vein over 3 hours for 4 Days
Melphalan
50 mg/m\^2 by vein over 15 minutes for 3 Days
Stem Cell Transplant
* Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest
* Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with advanced ovarian, fallopian or primary peritoneal cancer in second or later complete remission, or untreated or refractory relapse, defined as relapse within 6 months of prior platinum treatment or lack of response to salvage treatment.
3. No evidence of small bowel obstruction, as determined by CT scan of the abdomen and pelvis with oral and rectal contrast, within 30 days before the initiation of study treatment.
4. Adequate renal glomerular and tubular function, as defined by estimated serum creatinine clearance \>=60 ml/min, and urinary protein excretion \<=500 mg/day.
5. Adequate hepatic function, as defined by serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) \<=3 \* upper limit of normal (ULN); serum bilirubin and alkaline phosphatase \<=2 \* ULN or considered not clinically significant.
6. Adequate pulmonary function with Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and Carbon Monoxide Diffusing Capacity (DLCO) \>=50% of predicted, corrected for volume or hemoglobin.
7. Adequate cardiac function with left ventricular ejection fraction \>=45%. No uncontrolled arrhythmias or symptomatic cardiac disease.
8. Zubrod performance status \<2.
Exclusion Criteria
2. Patients with unresolved grade 3 or greater non-hematologic toxicity from previous therapy. Patients with grade 2 toxicity will be eligible at the discretion of the principal investigator.
3. Major surgery within 30 days before the initiation of study treatment
4. Radiotherapy within 21 days prior to initiation of study treatment
5. Patients with active Central Nervous System (CNS) disease.
6. Evidence of acute or chronic active hepatitis or cirrhosis. If positive hepatitis serology, discuss with Principal Investigator and consider liver biopsy.
7. Uncontrolled infection, including HIV or HTLV-1 infection.
8. Aspirin (\> 325 mg/day) use within 10 days before initiation of study treatment.
9. Ongoing uncontrolled hypertension (\>140/90 mm Hg on medication).
10. Non-healing wound or significant traumatic injury within 30 days before the initiation of study treatment
11. Previous autologous or allogeneic stem cell transplant during the past year.
12. Positive Beta HCG test in a woman with child-bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization.
18 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yago Nieto, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
U.T.M.D. Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
MD Anderson Cancer Center website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-0368
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.